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Prevalence of Alzheimer’s Dementia and Its Risk 
Factors in Community-Dwelling Elderly Koreans 
 
 
 
ObjectiveᄏWe estimated the prevalence of Alzheimer’s dementia (AD) and mild cognitive 
impairment (MCI) and their risk factors in an urban community setting, focusing especially 
on metabolic syndrome. 
MethodsᄏA two-phase investigation based on a door-to-door survey was performed. In 
Phase I, we administered the Korean version of the Mini-Mental State Examination (MMSE-
KC) of the Consortium to Establish a Registry for Alzheimer’s disease (CERAD-K). Assess-
ment Packet and the Korean version of the Geriatric Depression Scales (GDS-K) to all 706 
participants aged 65 years or older. In Phase II of the study, 175 persons underwent physical 
and neurological examinations according to the protocol of the CERAD-K clinical assess-
ment battery [CERAD-K (C)] and the neuropsychological assessment battery [CERAD-K 
(N)]. We also examined the association between cognitive decline and metabolic syn-
drome. AD and MCI were defined using the DSM-IV-TR criteria and the Clinical Dementia 
Rating (CDR) scales. 
ResultsᄏThe mean age (±SD) of the subjects was 74.3±16.7 years and the ratio of 
males to females was 53.2 to 46.8. The prevalence of Alzheimer’s dementia was 9.0%, while 
that of MCI was 32.9%. Old age and lower educational level had significant associations 
with cognitive decline in the elderly, but gender, years of alcohol intake or smoking, and 
metabolic syndrome were not associated with AD or MCI. 
ConclusionᄏIn this study, metabolic syndrome was not associated with Alzheimer’s AD 
or MCI. Information regarding an association between Alzheimer’s dementia and metabolic 
syndrome in this study will be helpful in formulating future public health policy and preven-
tion strategies in Korea. 
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Introduction 
 
Alzheimer’s dementia (AD) is a disease which is strongly associated with age, 
occurring in 1% of those aged 60-65, 6% of those aged 75-79, and 45% of those 
aged 95 or older.
1  The prevalence of AD is rising along with the increase in global
life expectancy. In Korea, the proportion of people aged 65 years and over is expected 
to increase from 7.3% in 2000 to 15.1% in 2020. 
2 Because the average age of society
is advancing and the number of patients with AD is increasing, it is important to main-
tain the quality of life in the elderly and to minimize the cost of medications and care 
by removing as many risk factors as possible for AD and cognitive impairment.
3 AD is 
one of the most distressing and burdensome mental health problems in the elderly.
4
Many studies have been conducted around the world on the prevalence of AD and its
risk factors. The prevalence of AD in persons aged 65 and older has been reported to be 
3.6-10.3% in Western countries,
5,6 1.8-4.6% in China, 3.7-6.7% in Japan,
7 and 9.5-
10.8% in Korea.
8,9 The inci dence of AD in cognitively normal individuals over age 65 
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has generally been reported to be 1-2% per year.
10 
Across the age continuum from middle to later life, 
the onset of AD is gradual and is believed to be pre-
ceded by an earlier state of mild cognitive impairment 
(MCI). The term, MCI, was originally used to describe 
an amnestic state, but has since been broadened to 
include impairments in other cognitive domains.   
It is now one of several terms which is used to de-
scribe a cognitive state intermediate between normal 
aging and AD, often with the implication that it is a risk 
factor or prodromal state for AD or other dementias.
11 
Community-based studies have reported MCI preva-
lences ranging from 2.8 to 6.1%.
12,13 In the large, na-
tionally representative Canadian Study of Health and 
Aging, the prevalence of MCI was about 16%, twice 
that of AD.
14 In the Cardiovascular Health Study, 6% of 
the sample had amnestic MCI and 16% had MCI with 
multiple cognitive deficits
15; 6% of all MCI cases and 
21.5% of all multiple deficit cases did not have memory 
impairment.13 In the Leipzig Longitudinal Study of the 
Aged, the prevalence of MCI varied from 3 to 20%, de-
pending on the definition of MCI.
16 Known risk factors 
for AD include advanced age, female gender, lower edu-
cational level, cerebrovascular disease, hypertension, ar-
rhythmia, hyperlipidemia, alcohol-related disorders, dia-
betes mellitus, and smoking. All of these can be modified 
or prevented to some degree.
17,18  
While hypertension is known to be a risk factor for 
cerebrovascular events and vascular dementia, recent 
studies show that midlife hypertension is also a risk 
factor for cognitive impairment and AD in later life.
3,17 
Cardiovascular and metabolic risk factors, such as hy-
pertension and diabetes, have been hypothesized to play 
roles in the pathogenesis of AD and in the development 
of vascular dementia.
19-22 
Metabolic syndrome, a clustering of several commonly 
occurring disorders that includes abdominal obesity, hy-
pertriglyceridemia, low high-density lipoprotein (HDL) 
level, hypertension, and hyperglycemia, has not been 
specifically investigated as a risk factor for cognitive 
impairment in the elderly. Metabolic syndrome may be 
a risk factor for cognitive impairment simply because it 
summarizes the combined effects of the risk factors as-
sociated with the component disorders. 
The prevalence of metabolic syndrome, like that of 
cognitive disorders, increases with age. If metabolic syn-
drome is associated with an increased risk of developing 
cognitive impairment, then early identification and treat-
ment of individuals suffering from metabolic disorder 
may offer opportunities for modifying the development 
of cognitive disorders.
23,24 
Obesity and sedentary lifestyles have become more 
common in Korea, just as they have in developed Western 
countries. It is therefore very important to identify and 
clarify the deleterious effects of modifiable behaviours 
in increasing the risk of outcomes, such as cognitive im-
pairment.
24 
This study aimed to estimate the prevalence of AD 
and mild cognitive impairment and to survey their risk 
factors, especially metabolic syndrome in older people 
in Busan, a metropolitan area of Korea.   
 
Methods 
 
This is a community study, which employed a two-
stage design to obtain estimates of the prevalence of AD 
and its risk factors, especially metabolic syndrome. The 
study was conducted from July 2005 through February 
2007 in Gaegeum 2 dong, Busanjin-gu, one of the 16 
districts in Busan, the second largest city in Korea. The to-
tal population of Gaegeum 2 dong was 16,817, and 1,215 
(7.22%) residents were aged 65 and older (established 
from resident registration records in January 2005).  
The institutional review board of the Medical College 
of Inje University, Busan Paik Hospital, Korea, approved 
the study protocol. All participants or family members 
provided informed consent. 
 
Phase I: Population survey   
During the period July 2005 through February 2006, 
1,215 elderly people were invited to participate in a sur-
vey, which involved them responding to a structured 
interview administered in their homes by two trained 
research nurses and seven psychiatrists. If the respon-
dent could not provide sufficient information without 
assistance, reliable informants (spouse, child, other rel-
atives, close friends, in that descending order) were also 
interviewed. The structured interview consisted of de-
mographic questions, past and present medical history, 
the Mini-Mental State Examination (MMSE-KC) of the 
Korean version of the Consortium to Establish a Registry 
for Alzheimer’s Disease Assessment Packet (CERAD-
K),
25 and the Korean version of the Geriatric Depres-
sion Scale (GDS-K).
26 
The demographic part of the structured interview 
consisted of questions on age, gender, education, height, 
weight, family members living with the subject, and 
previous or present occupation. The medical history in-
volved questions relating to hypertension, diabetes mellitus, 
stroke, major endocrine/hepatic/pulmonary/renal/cardiac 
disease, head trauma, seizures, encephalitis, Parkinson’s 
disease, alcohol abuse, depression, other major psychiat-
ric illnesses, and the use of prescription and/or nonpre-
scription medications.    
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Phase II: Clinical evaluation  
Each of the Phase I participants was placed in one of 
three groups according to performance on the MMSE-
KC: ‘good’ (MMSE-KC, 0-1.0 SDs below the mean 
score), ‘intermediate’ (MMSE-KC, 1.0-1.5 SDs below 
the mean score), or ‘poor’ (MMSE-KC≧1.5 SDs below 
the mean score).  
For the Phase II clinical evaluation, participants were 
then randomly sampled from each group using different 
sampling fractions. The group-specific sampling fractions 
were 20% for the ‘good’, 50% for the ‘intermediate’, and 
100% for the ‘poor’ performance groups. These sampling 
fractions were designed to increase the number of AD 
cases included in the study by giving greater weight to 
the selection of participants from the lower performing 
groups. 
The research physicians involved were blinded to the 
results of the survey in Phase I.   
The clinical evaluations were carried out from Sep-
tember 2006 to February 2007. by a psychiatrist with 
advanced training in AD and eight psychiatric residents, 
who conducted standardized clinical interviews and per-
formed physical and neurological examinations accord-
ing to the protocol of the Korean version of the CERAD 
Clinical Assessment Battery [CERAD-K (C)].
25 
Where necessary, reliable informants were interview-
ed to obtain accurate information about cognitive and 
functional changes and the medical histories of the par-
ticipants. We depended more heavily on the reports of 
informants than the test scores in evaluating illiterate or 
poorly educated subjects. We also used the medical and 
psychiatric history data and GDS-K
26 scores collected in 
the Phase I survey as reference information for the eval-
uation of each Phase II participant. This made it possible 
to save time and reduce the possible omission of major 
medical or psychiatric histories that might have affected 
the cognitive state of the participants. 
Two trained research nurses administered the eight 
neuropsychological tests from the Korean version of the 
CERAD neuropsychological assessment battery [CERAD-
K (N)].
25 These were the Verbal Fluency Test, the 15-
item Korean Version of the Boston Naming Test, the 
MMSE-KC, and the tests of Word List Memory, Con-
structional Praxis, Word List Recall, Word List Recogni-
tion, and Constructional Recall. 
The CERAD-K (C) and CERAD-K (N) were devel-
oped by translating the original English-language ver-
sion of the CERAD assessment packet
27 into Korean 
after considering cultural and linguistic differences. The 
cognitive tests in CERAD-K (C) and CERAD-K (N) 
have been shown to be reliable and valid equivalents of 
the tests in the English-language version of the CERAD 
clinical and neuropsychological assessment batteries.
25 
All participants in the Phase II evaluation were assess-
ed for metabolic syndrome. The presence of metabolic 
syndrome was determined with using the National Cho-
lesterol Education Program Third Adult Treatment Panel 
guidelines, which require the presence of at least three 
of the following: waist measurement of over 88 cm for 
women and over 102 cm for men, hypertriglyceridemia 
[≥150 mg/dL (≥1.69 mmol/L)], low HDL choles-
terol [<40 mg/dL (<1.03 mmol/L) in men and <50 mg/ 
dL  (<1.29 mmol/L) in women], high blood pressure 
(systolic,  ≥130 mmHg; diastolic, ≥85 mmHg, using 
the average of two seated measurements or current use 
of an antihypertensive medication), and high fasting 
glucose [≥110 mg/dL (≥6.10 mmol/L) or current use 
of an antidiabetic (insulin or oral agents) medication]. 
Lipid levels were measured after fasting. 
 
Diagnostic criteria and assessments 
The presence of AD was initially identified according 
to the diagnostic criteria in the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth edition-Text Revi-
sion (DSM-IV-TR).
28 Those Phase II respondents meet-
ing the DSM-IV-TR diagnostic criteria for AD were then 
further assessed to determine diagnostic subtypes. AD 
was diagnosed according to the criteria of the National 
Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA).
29 The diag-
nosis of vascular dementia (VD) was made according 
to the criteria of the National Institute of Neurological 
and Communicative Disorders and Stroke-Association 
Internationale pour la Recherche et l’Enseignement en 
Neurosciences (NINDS-AIREN) criteria.
30 A Modified 
Hachinski Ischemic Score
31 was also obtained for each 
case of dementia for reference purposes. All subjects 
with VD detected in this study scored greater than 4 on 
the Modified Hachinski Ischemic Scale. In this study, 
subjects with a probable or possible AD based on each 
set of diagnostic criteria were included, but those with 
VD were excluded. 
The diagnosis of MCI was established by evidence of 
memory impairment, preservation of general cognitive 
and functional abilities, and the absence of diagnosed 
AD. MCI is staged clinically at the 0.5 severity level on 
the Clinical Dementia Rating (CDR) scale.
32 The CDR 
scale is a dementia staging instrument used to rate the 
severity of cognitive impairment at five levels from 
none to a maximal 3 (rated as 0, 0.5, 1, 2, or 3) in each 
of six domains: memory, orientation, judgment and prob-
lem solving, function in community affairs, home and 
hobbies, and personal care with the last having no 0.5  
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impairment level.
32,33 
Based on collateral sources and an interview of the 
study subject, a global CDR score was derived from the 
individual ratings in each domain, so that a CDR-0 
indicated no dementia and CDRs 0.5, 1, 2, and 3 repre-
sented very mild, mild, moderate and severe dementia, 
respectively. The CDR-0.5 level was originally desig-
nated “questionable dementia or MCI”.
33,35 
A panel composed of eight psychiatrists reviewed all 
the data, including the raw materials from the clinical 
interviews, thephysical and neurological examinations, 
the neuropsychological test results, and the medical re-
cords. They then assigned the final diagnosis and CDR 
index
35 and divided all participants into three groups: 
healthy controls, and patients with MCI or AD. 
 
Statistical analyses 
ANOVA or t-tests were conducted to analyse group 
differences in terms of the demographic and metabolic 
syndrome data.
17,18 Univariate adjusted logistic regres-
sion analyses were used to explore the separate associ-
ations of age, education, weight and GDS-K score with 
the presence of AD. The possible overestimation of the 
odds ratios was corrected by adjusting to approximate 
risk ratios, using the method of Zhang and Yu,
36 The 
95% confidence intervals (CIs) were derived using the 
exact methods of a binomial parameter. A lack of over-
lap of the 95% CIs was used as the criterion for a stati-
stically significant difference between any two preva-
lences. All analyses were conducted using SAS software 
(version 8.2; SAS Institute, Cary, NC).  
 
Results 
 
Of the 1215 persons originally contacted, 706 (58.1%) 
participated in the Phase I population survey. And of 
these 252, 281, and 130 were assigned to the the good, 
intermediate and poor performance groups, respectively, 
according to their MMSE-KC score. Forty-three were 
excluded from the assignment due to incomplete infor-
mation. The MMSE-KC mean score (±SD) of all the 
Phase I participants was 22.1±7.2. The medical and 
psychiatric history data and GDS-K scores collected in 
the Phase I interview were used only as reference in-
formation in the Phase II clinical evaluation of each 
participant, and quantitative summaries of these data are 
not provided in this report. The reasons for the non-
participation in the Phase I survey by the remaining 509 
people were as follows: refusal (102 persons, 20.0%), 
incorrect address or change of address (327 persons, 
64.2%), not being home for three attempted visits (40 
persons, 7.9%), serious illness (30 persons, 5.9%), and 
death (10 persons, 2.0%). Of the 706 participants, 267 
from the three MMSE-KC score groups were invited to 
participate in the Phase II clinical evaluation, and 175 
(65.5%) completed the evaluation. The reasons for non-
completion of the Phase II clinical evaluation by the re-
maining 92 were as follows: refusal (43 persons, 47.1%), 
not being home for three attempted visits (29 persons, 
31.5%), admission for serious illness (16 persons, 17.4%), 
and death (4 persons, 4.35%). 
The subjects who did not participate in the Phase I 
survey or the Phase II clinical evaluation were not sig-
nificantly different in terms of age, education, or gender 
from those who did participate. The mean interval (±
SD) between the completion of Stage I and Phase II was 
394±48 days. The mean age (±SD) of the subjects was 
74.3±16.7 years, and the ratio of males to females was 
53.2 to 46.8. Of the 175 (65.5%) people who partici-
pated in the Phase II clinical evaluation, 16 met the DSM-
IV-TR criteria for AD, 57 were rated as having MCI
23 and 
102 had normal cognitive functioning (Figure 1). The 
overall prevalences, adjusted for those aged 65 and older 
in the population of Gaegeum 2 Dong, Busanjin-gu, were 
estimated to be 9.0% for AD, 32.9% for MCI, and 58.1% 
for normal cognitive functioning. 
The sociodemographic and clinical characteristics of 
the subjects participating in the Phase II clinical evalua-
tion are summarized in Table 1. The prevalence of MCI 
and AD and showed a statistically significant increase 
Total population (n=16,817) 
The elderly (n=1,215) 
20% 
MMSE-KC 
Good 
MMSE-KC 
(SD<1.0) 
n=252 
Intermediate 
MMSE-KC 
(1.0≀≦SD<1.5) 
n=281 
Poor 
MMSE-KC 
(SD≦1.5) 
n=130 
50% 100% 
Diagnostic procedure 
Normal 
n=102 
MCI 
n=57 
Alzheimer’s dementia 
n=16 
CERAD-K (C) 
CERAD-K (N) 
Phase I 
Phase II 
FIGURE 1. Summary of the study participants. MMSE-KC: Mini-
Mental State Examination-KC, CERAD-K: Consortium to Estab-
lish a Registry for Alzheimer’s disease-K, MCI: mild cognitive 
impairment.  
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with advancing age, lower levels of education, lower 
MMKE-KC scores, and higher GDS-K scores.   
The mean blood glucose and lipid levels and the 
prevalences of metabolic syndrome in the normal par-
ticipants and subjects with MCI and AD are shown in 
Table 2. The overall prevalence of metabolic syndrome 
in this study was 24.7% (25% in the normal cognitive 
group, 23.3% in the MCI group, and 30% in the AD 
group). We found no statistically significant differences 
in the mean scores for each metabolic syndrome factor 
and the prevalences of metabolic syndrome in the nor-
mal, MCI, and AD groups. 
To explore the separate associations of age, years of 
education, weight, waist circumference, and GDS-K score 
with the frequency of AD, odds ratios were calculated 
by a univariate logistic regression analysis. Older age, 
lower education, higher weight, and higher GDS-K scores 
were significantly associated with an increased preva-
lence of AD (Table 3). 
 
Discussion 
 
The prevalences of AD and MCI were estimated in 
elderly people in a metropolitan area of Korea, and the 
independent association of risk factors for AD, espe-
cially metabolic syndrome, was explored. The overall 
TABLE 1. Sociodemographic and clinical characteristics of the subjects
   Normal  MCI  AD 
  (N=102)  (N=57)  (N=16) 
p value 
Age (years)* 71.88  (±4.17) 73.82  (±4.51)  076.63 (±4.60)  <0.001 
Gender (M/F) 53/49  34/23  6/10  <0.273 
Years of education
†  005.85 (±04.63)  004.93 (±03.27)  001.69 (±03.09)  <0.001 
MMSE-KC*  023.12 (±03.15)  018.39 (±02.75)  013.00(±04.26)  <0.001 
GDS-K*  015.42 (±07.18)  019.91 (±05.64)  023.44 (±03.78)  <0.001 
Height (cm) 157.60 (±09.1)0 158.40 (±10.3)0 152.80 (±09.4)0  <0.111 
Weight (kg)
†  060.87 (±09.28)  058.74 (±10.90)  052.26 (±09.72)  <0.005 
Years of alcohol consumption  020.49 (±22.53)  027.33 (±25.40)  015.06 (±22.82)  <0.102 
Years of smoking  017.73 (±21.91)  019.62 (±24.53)  018.19 (±23.70)  <0.885 
History of hypertension (%) 41.18 34.55 43.75  <0.669 
History of diabetes mellitus (%)  17.65 16.36 12.50  <0.873 
History of head trauma (%) 14.71 25.93 18.75  <0.230 
*p<0.001,  †p<0.01. MMSE-KC: Korean version of the Mini-Mental Status Examination in the Consortium to Establish a Registry for Alz-
heimer’s disease (CERAD) assessment packet. MCI: mild cognitive impairment, AD: Alzheimer’s dementia, GDS-K: Geriatric Depression
Scales 
 
TABLE 2. Mean blood glucose and lipid levels and prevalence of metabolic syndrome in normal participants and subjects with MCI and AD
 Normal  MCI  AD 
 102  57  16 
p value 
Glucose (mg/dL) 117.5  (±41.7) 114.6  (±049.8) 110.5  (±028.5) 0.889 
Total cholesterol (mg/dL) 192.0  (±42.2) 194.6  (±035.5) 193.1  (±041.5) 0.957 
Triglycerides (mg/dL) 134.6  (±72.3) 152.6  (±110.0) 185.5  (±143.3) 0.321 
LDL cholesterol (mg/dL) 118.0  (±36.5) 114.1  (±031.8) 112.9  (±044.2) 0.854 
HDL cholesterol (mg/dL)  053.2 (±08.7)  058.9 (±022.2)  052.5 (±016.0) 0.259 
Systolic blood pressure (mmHg) 112.1  (±06.8) 110.5  (±007.4) 111.3  (±009.6) 0.443 
Diastolic blood pressure (mmHg)  070.9 (±05.6)  071.4 (±006.4)  070.6 (±004.4) 0.827 
Waist circumference (cm)*  085.4 (±08.6)  081.9 (±008.8)  081.3 (±008.5) 0.022 
Metabolic syndrome (%) 50.0%  37.8%  40.0%  0.536 
MCI: mild cognitive impairment, AD: Alzheimer’s dementia, LDL: low-density lipoprotein, HDL: high-density lipo-protein 
 
TABLE 3. Correlation of significant risk factors with AD 
   Odds ratio (95% CI) p  value 
Age* 1.20  (1.07–1.35) 0.001 
Years of education*  0.74 (0.62–0.90) 0.002 
Weight* 0.92  (0.87–0.98) 0.004 
Waist circumference  0.96 (0.91–1.02) 0.219 
GDS-K scores*  1.20 (1.07–1.34) 0.001 
AD: Alzheimer’s dementia, GDS-K: Korean version of the Geri-
atric Depression Scale 
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prevalence, adjusted for the older population of Gaegeum 
2 dong, Busanjin-gu, was estimated to be 9.0% for AD 
and 32.9% for MCI. The results of this study suggest 
that old age and low educational level are risk factors 
for AD and MCI, and that in this study population, met-
abolic syndrome had no significant association with AD 
or MCI. 
The estimated prevalence of AD of 9.0% is similar to 
that from a study in Seoul.
7 However, lower prevalences 
have been found in urban populations in Japan and 
China.
37,40,41 
The estimated prevalence of MCI was 32.9%. The 
reported prevalences and incidences of MCI or prede-
mentia syndromes vary from study to study because of 
the different diagnostic criteria used and different sam-
pling and assessment procedures. MCI is thought to be a 
prodromal phase of AD and therefore highly predictive 
of subsequent “conversion”.
42 In an Italian study, the 
prevalence was 9.5% for cognitive impairment [not de-
mented (CIND)] and 16.1% for MCI.
43 
Consistent with other studies,
40,41,44 the prevalence of 
AD and MCI increased rapidly with advancing age. 
Many studies have reported old age, low educational 
level, female gender, a family history of AD, and a 
history of head trauma to be risk factors for AD.
44 Our 
findings also pointed to old age and low educational 
level being significant risk factors in the development of 
AD and MCI (Table 1). 
Epidemiologic data supporting the cognitive reserve 
hypothesis include observations that higher educational 
and occupational attainment is associated with a decrea-
sed risk of AD. Factors other than education and oc-
cupation might also provide a reserve against the patho-
logic changes occurring in AD. More highly educated 
persons may have a greater cognitive reserve, and this 
may postpone the clinical manifestations of AD.
45-48 
Many studies have also reported that AD was more 
prevalent in women, while a few have reported that the 
prevalence was higher in men, or at least equal between 
the two genders.
48,49 Another Korean study showed that 
the overall frequency of AD in women was twice that in 
men, and the gender difference in the prevalence of AD 
was statistically significant.
9 In the present study, how-
ever, we found no gender difference. 
We explored the separate associations of each factor 
of metabolic syndrome with the prevalence of AD and 
MCI. However, neither metabolic syndrome nor any of 
its component factors were associated with an increased 
frequency of AD or MCI (Table 2). These results were 
similar to those of two other prospective studies that 
found no association between lipoprotein levels and the 
risk of AD. 
Metabolic syndrome also appears to predispose peo-
ple to cognitive dysfunction and AD.
50 In elderly women, 
metabolic syndrome may be an important contributor to 
the worsening of memory, an essential feature of MCI.
51 
The findings of studies that have investigated the rela-
tionship between serum lipoprotein levels and the risk 
of cognitive impairment are conflicting. Some cross-
sectional studies suggest that high total cholesterol lev-
els are associated with an increased risk of AD, while 
others report that low total cholesterol levels are asso-
ciated with the rvisk of developing AD.
52-54 In one study 
of more than 1,000 elderly people, a higher baseline low-
density lipoprotein (LDL) cholesterol level was associ-
ated with an increased risk of developing stroke-related 
dementia, but not with the risk of developing AD.
55,56 
Another study reported a statistically significant as-
sociation between lower total cholesterol levels and higher 
rates of cognitive decline in older populations, but its 
clinical significance remains unclear.
57,58 I n  a n  I t a l i a n  
study of elderly people, those who converted from MCI 
to AD tended to have higher serum HDL levels and lower 
serum folate levels.
42 
Even when using the same diagnostic criteria no clear 
agreement exists among clinicians and researchers re-
garding the degree of functional impairment that is suf-
ficient to warrant a diagnosis of AD.
7 This issue may be 
one of the major reasons for the varying estimates of 
AD across different populations. Our results were based 
on systematic clinical evaluations and the Korean ver-
sion of the CERAD battery, including some psychometric 
tests, thus potentially improving the discrimination be-
tween AD, MCI, major depression, and healthy controls.
7,19 
To reduce false-negatives, eight trained and experi-
enced psychiatrists and two trained research nurses 
performed face-to-face clinical diagnostic evaluations of 
all participants assessed in Phase I and Phase II. 
Although care was taken to avoid misdiagnosing AD 
because of a low level of education or intellectual disa-
bility, overall response rates in this study were 58.1% of 
the total population in the Phase I survey and 24.8% in 
the Phase II clinical evaluation. The response rate for 
Phase I was somewhat lower than that of a rural study in 
Korea (85.2% in Suh et al.
53). However, it was some-
what higher than the response rates found in other urban 
studies (37.7% in Cho et al.
36 and 53.8% in Bae et al.
37). 
The possibility exists that the prevalences of AD and 
MCI were underestimated in this study. A major cause 
of the low response rate was the long interval between 
the Phase I and Phase II evaluations. As in previous 
studies, people who lived in an affluent residential area 
frequently refused to participate in the study despite 
three visits for enrollment.
38,39  
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Clearly, this study has some limitations. First, the 
study included only noninstitutionalized elderly people. 
If institutionalized people had been included, it is likely 
that the estimated prevalence of AD would have been 
higher. However, this may be of little importance be-
cause institutional care for AD patients is not common 
in Koreawhere most AD patients live with their families. 
Secondly, AD was confirmed according to DSM-IV-TR 
and NINDS-ADRDA criteria. If subjects with a di-
agnosis of VD were excluded by the panel and did not 
contribute the estimated prevalence rate of AD. Further-
more, neuroimaging data were not available for all the 
AD patients. All of these factors may have contributed 
to an underestimation of the frequency of AD. 
The prevalences for AD and MCI were estimated to 
be 9.0% and 32.9% respectively when adjusted for the 
older population of Gaegeum 2 dong, Busanjin-gu. The 
results suggest that whereas old age and low educational 
level are risk factors for AD and MCI, metabolic syndrome 
had no significant association with either AD or MCI. 
Further longitudinal, prospective community studies are 
needed to test the hypothesis that the epidemiological 
transition into AD is causally related to modifiable risk 
factors in the elderly. 
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